Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Eloralintide · 7 trials · 6 indications
Change from Baseline in the WOMAC Pain Subscale Score
Least squares (LS) means were calculated using a mixed-model repeated measures (MMRM) model for post-baseline measures: Variable = Treatment + Time + Sex + Baseline BMI Category + Baseline + Time\*Sex +Time\*Baseline BMI Category + Treatment\*Time + Time\*Baseline. Variance-Covariance structure (Percent Change from Baseline) = Unstructured.
A summary of TEAEs and SAEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| Eloralintide (YSA1) | EXPERIMENTAL | Participants will receive eloralintide subcutaneously (SC) |
| Placebo (YSA1) | PLACEBO_COMPARATOR | Participants will receive placebo SC |
| Eloralintide (YSA2) | EXPERIMENTAL | Participants will receive eloralintide SC |
| Placebo (YSA2) | PLACEBO_COMPARATOR | Participants will receive placebo SC |
| Eloralintide (YOA1) | EXPERIMENTAL | Participants will receive eloralintide subcutaneously (SC) |
| Placebo (YOA1) | PLACEBO_COMPARATOR | Participants will receive placebo SC |
| Eloralintide (YOA2) | EXPERIMENTAL | Participants will receive eloralintide SC |
| Placebo (YOA2) | PLACEBO_COMPARATOR | Participants will receive placebo SC |
| Eloralintide Dose 1 | EXPERIMENTAL | Participants will receive eloralintide subcutaneously (SC) |
| Eloralintide Dose 2 | EXPERIMENTAL | Participants will receive eloralintide SC |
| Eloralintide Dose 3 | EXPERIMENTAL | Participants will receive eloralintide SC |
| Eloralintide Dose 4 | EXPERIMENTAL | Participants will receive eloralintide SC |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo SC |
| 1 mg Eloralintide | EXPERIMENTAL | Participants received eloralintide 1 milligram (mg) SC QW for 48 weeks. |
| 3 mg Eloralintide | EXPERIMENTAL | Participants received eloralintide 3 mg SC QW for 48 weeks. |
| 6 mg Eloralintide | EXPERIMENTAL | Participants received eloralintide 6 mg SC QW for 48 weeks. |
| 9 mg Eloralintide | EXPERIMENTAL | Participants received eloralintide 9 mg SC QW for 48 weeks. |
| 6/9 mg Eloralintide | EXPERIMENTAL | Participants received eloralintide 6 mg SC QW for 20 weeks, followed by eloralintide 9 mg SC QW for 28 weeks, for a total treatment duration of 48 weeks. |
| 3/6/9 mg Eloralintide | EXPERIMENTAL | Participants received eloralintide 3 mg SC QW for 4 weeks, followed by eloralintide 6 mg SC QW for 4 weeks, followed by eloralintide 9 mg SC QW for 40 weeks, for a total treatment duration of 48 weeks. |
| Eloralintide Cohort 1 | EXPERIMENTAL | Eloralintide administered subcutaneously (SC) |
| Eloralintide Cohort 2 | EXPERIMENTAL | Eloralintide administered SC |
| Eloralintide Cohort 3 | EXPERIMENTAL | Eloralintide administered SC |
| Eloralintide Cohort 4 | EXPERIMENTAL | Eloralintide administered SC |
| Eloralintide (Reference) | ACTIVE_COMPARATOR | Participants will receive eloralintide reference formulation administered subcutaneously (SC). |
| Eloralintide (Test) | EXPERIMENTAL | Participants will receive eloralintide test formulation administered SC. |
| Eloralintide | EXPERIMENTAL | Eloralintide administered subcutaneously (SC) |
| Name | Type | Description |
|---|---|---|
| Eloralintide | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
| Acetaminophen | DRUG | Administered Oral Solution |
Inclusion Criteria: * Confirmed history of moderate-to-severe OSA * Have an AHI ≥ 15 on polysomnography (PSG) as part of the study at screening * Have a BMI ≥27 kg/m2 at screening * Have a stable body weight (\<5% body weight change) for 90 days prior to screening * Have a history of at least one s...
Top 20 of 32 competitors
Eloralintide is an investigational small molecule being studied for weight management in adults with obesity or overweight. It is also listed for other conditions including osteoarthritis, sleep apnea, and healthy volunteer studies, though its primary clinical trials focus on obesity and overweight populations.
Eloralintide is a peptide-based small molecule, classified under the -tide (peptide) target class. Its specific molecular target is not disclosed in the available clinical trial information, but it is being evaluated for its effects on body weight regulation in obesity and overweight.
Eloralintide is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY. The company is conducting multiple clinical trials to evaluate the drug's safety and efficacy in weight management.
Eloralintide is in Phase 1 clinical development, with one Phase 3 trial currently recruiting participants. The Phase 3 study is investigating the drug in adults with obesity or overweight without type 2 diabetes, while earlier-phase trials have been completed or are ongoing.
Eloralintide has four registered clinical trials. NCT07321886 is a Phase 3 recruiting study in obesity or overweight without type 2 diabetes. NCT07738614 is a Phase 1 recruiting study in obesity or overweight. NCT06916091 and NCT06230523 are completed trials in similar populations.
Yes, Eloralintide is also known as LY3841136. Clinical trial records list both names interchangeably, with studies titled using either Eloralintide (LY3841136) or just LY3841136, confirming they refer to the same investigational drug.